PHARMACOKINETICS OF THE DIGOXIN-QUINIDINE INTERACTION VIA MIXED-EFFECT MODELING

被引:26
|
作者
WILLIAMS, PJ
LANE, J
MURRAY, W
MERGENER, MA
KAMIGAKI, M
机构
[1] UNIV CALIF SAN DIEGO,MED CTR,DEPT PHARM,SAN DIEGO,CA 92103
[2] UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143
关键词
D O I
10.2165/00003088-199222010-00006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
It was the purpose of this study to evaluate the effect of quinidine administration on the population estimates of the volume of distribution (Vd(pop)) and clearance (CL(pop)) of digoxin. The data collected on 94 patients included 230 measured serum digoxin concentrations, height, age, sex, weight (wt), serum creatinine, history of digoxin and quinidine administration and the presence or absence of congestive heart failure (CHF). Using the NONMEM software program, estimates were obtained for CL(pop) and Vd(pop). Variables tested for inclusion in the CL(pop) model were creatinine clearance (CL(CR)), CHF, wt, ideal bodyweight, quinidine (QUIN) [both as a discrete variable and in a dose-dependent manner], and body surface area. Variables tested for inclusion in the Vd(pop) model were CL(CR), wt, ideal bodyweight, body surface area and quinidine. During model building a p-value of 0.05 was chosen for variable inclusion. The final model was as follows: CL(pop) (L/h) = (3.1 + 0.0516 x CL(CR)) x QUIN Vd(pop) (L) = (4.03 + 0.0832 x CL(CR)) x wt F = 0.82 where F is bioavailability. In the above, QUIN is 0.567 if quinidine is being concurrently administered and 1.0 if it is not. The coefficient of variation (CV) of CL(pop) was 44% while that of Vd(pop) was 48%. The residual intrasubject CV was 26%. These results compare favourably with previously derived methods of estimating digoxin CL(pop) and Vd(pop) but may improve on those methods due to the inclusion of quinidine in the model. These better estimates should result in improved initial dosage of digoxin.
引用
收藏
页码:66 / 74
页数:9
相关论文
共 50 条
  • [1] Mixed-effect modeling for detection and evaluation of drug interactions: Digoxin-quinidine and digoxin-verapamil combinations
    Bauer, LA
    Horn, JR
    Pettit, H
    [J]. THERAPEUTIC DRUG MONITORING, 1996, 18 (01) : 46 - 52
  • [2] DIGOXIN-QUINIDINE INTERACTION
    REID, PR
    MEEK, AG
    [J]. JOHNS HOPKINS MEDICAL JOURNAL, 1979, 145 (06): : 227 - 229
  • [3] THE DIGOXIN-QUINIDINE INTERACTION
    DOHERTY, JE
    [J]. ANNUAL REVIEW OF MEDICINE, 1982, 33 : 163 - 170
  • [4] DIGOXIN-QUINIDINE INTERACTION
    MEISEL, S
    TANNENBAUM, R
    [J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1980, 14 (12): : 869 - 869
  • [5] DIGOXIN-QUINIDINE INTERACTION
    POWELL, JR
    FENSTER, PE
    HAGER, WD
    [J]. ANNALS OF INTERNAL MEDICINE, 1981, 94 (04) : 540 - 540
  • [6] REDUCTION OF DIGOXIN EFFECT DURING THE DIGOXIN-QUINIDINE INTERACTION
    DAS, G
    BARR, CE
    CARLSON, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (03) : 317 - 321
  • [7] EFFECT OF ELECTROLYTE CONCENTRATIONS ON THE DIGOXIN-QUINIDINE INTERACTION
    LABROSSE, KR
    VEIT, C
    FRAKES, M
    MCBRIDE, JW
    MCCOY, HG
    [J]. CLINICAL CHEMISTRY, 1981, 27 (06) : 1088 - 1088
  • [8] ALGORITHM FOR DIGOXIN-QUINIDINE INTERACTION
    LEE, M
    HOPKINS, L
    [J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1980, 14 (01): : 57 - 59
  • [9] DIGOXIN-QUINIDINE INTERACTION - REPLY
    HAGER, WD
    FENSTER, P
    MAYERSOHN, M
    PERRIER, D
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1979, 301 (13): : 727 - 728
  • [10] MECHANISM OF THE DIGOXIN-QUINIDINE INTERACTION
    HOOYMANS, PM
    MERKUS, FWHM
    [J]. PHARMACY INTERNATIONAL, 1980, 1 (08): : 158 - 161